Skip to main content

Advertisement

SpringerLink
Log in

Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy

  • Alimentary Tract
  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

S-1, an oral fluoropyrimidine, has been shown to have excellent activity against gastric cancer in two phase II studies and is widely used in Japan. However, the long-term outcomes of patients after S-1 monotherapy for metastatic gastric cancer are unclear. The aim of this study was to investigate the long-term outcomes in metastatic gastric cancer patients who had initially received S-1 monotherapy.

Methods

Ninety-two previously untreated patients with advanced gastric cancer received S-1 monotherapy as first-line chemotherapy at the National Cancer Center Hospital East, Kashiwa, Japan, and then the long-term outcomes and characteristics of long-term survivors were analyzed retrospectively. Multivariate analysis of prognostic factors was performed by the Cox proportional hazard method.

Results

With a median follow-up of 3.1 years, the median progression-free survival time was 4.6 months. The median survival time was 11.9 months, with 1-, 2- and 3-year survival rates of 49.1%, 22.8%, and 9.8%, respectively. Multivariate analysis showed that good performance status (P = 0.0004) and only one metastatic site (P = 0.0048) were significant independent prognostic factors. Among 48 patients with a single metastatic site, 22 with peritoneal metastasis had longer survival times (median survival, 24 months) than patients with metastasis at other sites. Among the nine 3-year survivors, six had peritoneal metastases alone.

Conclusions

The survival outcomes after S-1 monotherapy are promising, especially in patients with good performance status and a single metastatic site. Our findings suggest that, among patients with a single metastatic site, those with peritoneal metastases alone have a chance for long-term survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch (1993) ArticleTitleModified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37–41 Occurrence Handle8508427 Occurrence Handle10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P Occurrence Handle1:STN:280:ByyB1cvlvFM%3D

    Article  PubMed  CAS  Google Scholar 

  2. B Glimelius K Hoffman U Haglund O Nyren PO Sjoden (1994) ArticleTitleInitial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189–90 Occurrence Handle8186165 Occurrence Handle1:STN:280:ByuB2c3mvVY%3D

    PubMed  CAS  Google Scholar 

  3. S Pyrhonen T Kuitunen P Nyandoto M Kouri (1995) ArticleTitleRandomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587–91 Occurrence Handle7533517 Occurrence Handle1:STN:280:ByqC1cnjvVA%3D

    PubMed  CAS  Google Scholar 

  4. JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper et al. (1999) ArticleTitleLong-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer. Results of a randomized trial Br J Cancer 80 269–72 Occurrence Handle10390007 Occurrence Handle10.1038/sj.bjc.6690350 Occurrence Handle1:CAS:528:DyaK1MXjtFyksbo%3D

    Article  PubMed  CAS  Google Scholar 

  5. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem et al. (2000) ArticleTitleFinal results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer. A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648–57 Occurrence Handle10894863 Occurrence Handle1:CAS:528:DC%2BD3cXls12iurk%3D

    PubMed  CAS  Google Scholar 

  6. A Ohtsu Y Shimada K Shirao N Boku I Hyodo H Saito et al. (2003) ArticleTitleRandomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205) J Clin Oncol 21 54–9 Occurrence Handle12506170 Occurrence Handle10.1200/JCO.2003.04.130 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWru7k%3D

    Article  PubMed  CAS  Google Scholar 

  7. NK Kim YS Park DS Heo C Suh SY Kim KC Park et al. (1993) ArticleTitleA phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813–8 Occurrence Handle8508349 Occurrence Handle10.1002/1097-0142(19930615)71:12<3813::AID-CNCR2820711205>3.0.CO;2-5 Occurrence Handle1:STN:280:ByyB1cvkvFQ%3D

    Article  PubMed  CAS  Google Scholar 

  8. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni et al. (2006) ArticleTitlePhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991–7 Occurrence Handle17075117 Occurrence Handle10.1200/JCO.2006.06.8429 Occurrence Handle1:CAS:528:DC%2BD28Xht1GnurzJ

    Article  PubMed  CAS  Google Scholar 

  9. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D

    Article  PubMed  CAS  Google Scholar 

  10. W Koizumi M Kurihara S Nakano K Hasegawa (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fuorouracil, in advanced gastric cancer Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D

    Article  PubMed  CAS  Google Scholar 

  11. F Nagashima A Ohtsu S Yoshida K Ito (2005) ArticleTitleJapanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer Gastric Cancer 8 6–11 Occurrence Handle15747168 Occurrence Handle10.1007/s10120-004-0306-3

    Article  PubMed  Google Scholar 

  12. O Kobayashi K Konishi M Kanari H Cho T Yoshikawa A Tsuburaya et al. (2002) ArticleTitleUnusual survival for more than 2 years with peritoneal metastases of gastric cancer Gastric Cancer 5 47–50 Occurrence Handle12021860 Occurrence Handle10.1007/s101200200007

    Article  PubMed  Google Scholar 

  13. K Fujitani T Tsujinaka M Hirao (2003) ArticleTitleFeasibility study of S-1 for respectable gastric cancer with peritoneal seeding Hepatogastroenterology 50 889–92 Occurrence Handle12828112

    PubMed  Google Scholar 

  14. H Osugi N Takada M Takemura S Kaseno S Lee M Ueno et al. (2002) ArticleTitleOral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination Oncol Rep 9 811–5 Occurrence Handle12066214 Occurrence Handle1:CAS:528:DC%2BD38XltlGrsrk%3D

    PubMed  CAS  Google Scholar 

  15. T Mori Y Fujiwara M Yano S Tamura T Yasuda S Takiguchi et al. (2003) ArticleTitleExperimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer Gastric Cancer 6 13–8 Occurrence Handle12775014 Occurrence Handle10.1007/s10120-003-0226-7

    Article  PubMed  Google Scholar 

  16. M Yoshida A Ohtsu N Boku Y Miyata K Shirao Y Shimada et al. (2004) ArticleTitleLong-term survival and prognostic factors with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study Jpn J Clin Oncol 34 654–9 Occurrence Handle15613554 Occurrence Handle10.1093/jjco/hyh120

    Article  PubMed  Google Scholar 

  17. P Rougier M Ducreux M Mahjoubi JP Pignon S Bellefqih J Oliveira et al. (1994) ArticleTitleEfficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis Eur J Cancer 30A 1263–9 Occurrence Handle7999410 Occurrence Handle10.1016/0959-8049(94)90170-8 Occurrence Handle1:STN:280:ByqD1M3jslc%3D

    Article  PubMed  CAS  Google Scholar 

  18. C Louvet F Carrat F Mal M Mabro K Beerblock JC Vaillant et al. (2003) ArticleTitlePrognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen) Cancer Invest 21 14–20 Occurrence Handle12643005 Occurrence Handle10.1081/CNV-120016399 Occurrence Handle1:CAS:528:DC%2BD3sXisF2mtrg%3D

    Article  PubMed  CAS  Google Scholar 

  19. I Chau AR Norman D Cunningham JS Waters J Oates PJ Ross (2004) ArticleTitleMultivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data J Clin Oncol 22 2395–403 Occurrence Handle15197201 Occurrence Handle10.1200/JCO.2004.08.154

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan

    Ayumu Hosokawa & Toshiro Sugiyama

  2. Division of Gastrointestinal Oncology and Digestive Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan

    Ayumu Hosokawa, Atsushi Ohtsu, Toshihiko Doi, Santa Hattori, Takashi Kojima, Tomonori Yano, Keiko Minashi, Manabu Muto & Shigeaki Yoshida

Authors
  1. Ayumu Hosokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiro Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Ohtsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshihiko Doi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Santa Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomonori Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keiko Minashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Manabu Muto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shigeaki Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hosokawa, A., Sugiyama, T., Ohtsu, A. et al. Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy. J Gastroenterol 42, 533–538 (2007). https://doi.org/10.1007/s00535-007-2059-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-007-2059-3

Key words

Search

Navigation